Vaginal microbiota associated with oncogenic HPV in a cohort of HPV-vaccinated women living with HIV.


Journal

International journal of STD & AIDS
ISSN: 1758-1052
Titre abrégé: Int J STD AIDS
Pays: England
ID NLM: 9007917

Informations de publication

Date de publication:
Aug 2022
Historique:
pubmed: 2 7 2022
medline: 20 8 2022
entrez: 1 7 2022
Statut: ppublish

Résumé

Women living with HIV (WLWH) experience higher rates of human papillomavirus (HPV) infection and cervical cancer than women without HIV. Changes in the vaginal microbiome have been implicated in HPV-related disease processes such as persistence of high-risk HPV infection but this has not been well defined in a population living with HIV. Four hundred and 20 girls and WLWH, age ≥9, across 14 clinical sites in Canada were enrolled to receive three doses of quadrivalent HPV vaccine for assessment of vaccine immunogenicity. Blood, cervical cytology, and cervico-vaginal swabs were collected. Cervico-vaginal samples were tested for HPV DNA and underwent microbiota sequencing. Principal component analysis (PCA) and hierarchical clustering generated community state types (CSTs). Relationships between taxa and CSTs with HPV infection were examined using mixed-effects logistic regressions, Poisson regressions, or generalized linear mixed-effects models, as appropriate. Three hundred and fifty-six cervico-vaginal microbiota samples from 172 women were sequenced. Human papillomavirus DNA was detected in 211 (59%) samples; 110 (31%) contained oncogenic HPV. Sixty-five samples (18%) were taken concurrently with incident oncogenic HPV infection and 56 (16%) were collected from women with concurrent persistent oncogenic HPV infection. No significant associations between taxa, CST, or microbial diversity and HPV-related outcomes were found. However, we observed weak associations between a dysbiotic microbiome and specific species, including

Sections du résumé

BACKGROUND
Women living with HIV (WLWH) experience higher rates of human papillomavirus (HPV) infection and cervical cancer than women without HIV. Changes in the vaginal microbiome have been implicated in HPV-related disease processes such as persistence of high-risk HPV infection but this has not been well defined in a population living with HIV.
METHODS
Four hundred and 20 girls and WLWH, age ≥9, across 14 clinical sites in Canada were enrolled to receive three doses of quadrivalent HPV vaccine for assessment of vaccine immunogenicity. Blood, cervical cytology, and cervico-vaginal swabs were collected. Cervico-vaginal samples were tested for HPV DNA and underwent microbiota sequencing.
RESULTS
Principal component analysis (PCA) and hierarchical clustering generated community state types (CSTs). Relationships between taxa and CSTs with HPV infection were examined using mixed-effects logistic regressions, Poisson regressions, or generalized linear mixed-effects models, as appropriate. Three hundred and fifty-six cervico-vaginal microbiota samples from 172 women were sequenced. Human papillomavirus DNA was detected in 211 (59%) samples; 110 (31%) contained oncogenic HPV. Sixty-five samples (18%) were taken concurrently with incident oncogenic HPV infection and 56 (16%) were collected from women with concurrent persistent oncogenic HPV infection.
CONCLUSIONS
No significant associations between taxa, CST, or microbial diversity and HPV-related outcomes were found. However, we observed weak associations between a dysbiotic microbiome and specific species, including

Identifiants

pubmed: 35775280
doi: 10.1177/09564624221109686
pmc: PMC9388949
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

847-855

Subventions

Organisme : CIHR
ID : MOP 136784
Pays : Canada
Organisme : CIHR
ID : CTN 236
Pays : Canada

Références

mBio. 2019 Feb 19;10(1):
pubmed: 30782659
Front Cell Infect Microbiol. 2020 Nov 05;10:540900
pubmed: 33251154
Eur J Obstet Gynecol Reprod Biol. 2005 Aug 1;121(2):226-32
pubmed: 16054967
J Infect Dis. 2014 Dec 15;210 Suppl 3:S616-21
pubmed: 25414415
J Infect Dis. 2013 Aug 1;208(3):454-62
pubmed: 23624362
PLoS One. 2020 Jul 9;15(7):e0235682
pubmed: 32645030
Am J Reprod Immunol. 2014 Jun;71(6):531-6
pubmed: 24661438
Obstet Gynecol. 1994 Oct;84(4):591-7
pubmed: 8090399
PLoS One. 2016 Jan 11;11(1):e0146510
pubmed: 26751374
N Engl J Med. 2005 Nov 3;353(18):1899-911
pubmed: 16267321
BJOG. 2018 Feb;125(3):309-315
pubmed: 28278350
BMC Womens Health. 2019 Feb 6;19(1):30
pubmed: 30728029
Int J Infect Dis. 2015 Apr;33:219-21
pubmed: 25697074
Clin Lab Med. 2014 Dec;34(4):747-61
pubmed: 25439274
J Clin Pathol. 2002 Apr;55(4):244-65
pubmed: 11919208
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Annu Rev Microbiol. 2012;66:371-89
pubmed: 22746335
NPJ Biofilms Microbiomes. 2020 Oct 12;6(1):39
pubmed: 33046723
Lancet. 2007 Sep 8;370(9590):890-907
pubmed: 17826171
BMC Infect Dis. 2013 Jun 10;13:271
pubmed: 23758857
Front Public Health. 2021 Jan 08;8:587298
pubmed: 33490017
Front Microbiol. 2017 Nov 15;8:2224
pubmed: 29187837
AIDS. 2012 Nov 13;26(17):2211-22
pubmed: 22874522
Microb Ecol Health Dis. 2015 May 29;26:27663
pubmed: 26028277
Int J Cancer. 2020 Mar 15;146(6):1514-1522
pubmed: 31173641
Clin Microbiol Infect. 2015 Jul;21(7):674.e1-9
pubmed: 25752224
J Antimicrob Chemother. 2013 Sep;68(9):2015-25
pubmed: 23657804
mBio. 2015 Oct 06;6(5):e01084-15
pubmed: 26443453
Virology. 2016 Jun;493:247-54
pubmed: 27065342
Immunity. 2015 May 19;42(5):965-76
pubmed: 25992865
Sci Rep. 2015 Nov 17;5:16865
pubmed: 26574055
Mucosal Immunol. 2016 May;9(3):621-33
pubmed: 26349657
Sex Transm Dis. 2021 Jul 1;48(7):499-507
pubmed: 33346587
J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):230-234
pubmed: 31917750
Clin Infect Dis. 2019 Feb 15;68(5):788-794
pubmed: 29985988
Appl Environ Microbiol. 2009 May;75(9):2889-98
pubmed: 19270139
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:2-13
pubmed: 28964706
N Engl J Med. 1997 Nov 6;337(19):1343-9
pubmed: 9358128
AIDS. 2018 Mar 27;32(6):795-808
pubmed: 29369827
J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):226-236
pubmed: 29916960
Clin Infect Dis. 2018 Aug 1;67(4):606-613
pubmed: 29617952
Clin Infect Dis. 2013 Dec;57(11):1638-47
pubmed: 23899679
BMC Infect Dis. 2005 Sep 30;5:79
pubmed: 16194280
BJOG. 2017 Mar;124(4):606-611
pubmed: 28224747

Auteurs

Elisabeth McClymont (E)

Department of Obstetrics and Gynecology, 198113University of British Columbia, Vancouver, BC, Canada.
469220Canadian HIV Trials Network, Vancouver, BC, Canada.

Arianne Y Albert (AY)

574481Women's Health Research Institute, Vancouver, BC, Canada.

Christine Wang (C)

Faculty of Medicine, 12358University of British Columbia, Vancouver, BC, Canada.

Scott J Dos Santos (SJ)

Department of Veterinary Microbiology, 70399University of Saskatchewan, Saskatoon, SK, Canada.

François Coutlée (F)

Département de Microbiologie Médicale et Infectiologie, 5622l'Université de Montréal, Montréal, QC, Canada.

Marette Lee (M)

Department of Obstetrics and Gynecology, 198113University of British Columbia, Vancouver, BC, Canada.

Sharon Walmsley (S)

Toronto General Hospital Research Institute, University of Toronto, 7989University Health Network, Toronto, ON, Canada.
Dalla Lana School of Public Health, 274071University of Toronto, Toronto, ON, Canada.

Nancy Lipsky (N)

574481Women's Health Research Institute, Vancouver, BC, Canada.

Mona Loutfy (M)

Women's College Research Institute, University of Toronto, Toronto, ON, Canada.

Sylvie Trottier (S)

Infectious Diseases Research Centre, 4440Université Laval, Québec City, QC, Canada.

Fiona Smaill (F)

Department of Pathology and Molecular Medicine, 3710McMaster University, Hamilton, ON, Canada.

Marina B Klein (MB)

54473McGill University Health Centre, Montreal, QC, Canada.

Mark H Yudin (MH)

Women's College Research Institute, University of Toronto, Toronto, ON, Canada.
Department of Obstetrics and Gynecology, University of Toronto, 574538St. Michael's Hospital, Toronto, ON, Canada.

Marianne Harris (M)

Faculty of Medicine, 12358University of British Columbia, Vancouver, BC, Canada.
198129British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.

Wendy Wobeser (W)

Departments of Public Health and Molecular & Biomedical Sciences, 4257Queen's University, Kingston, ON, Canada.

Janet E Hill (JE)

Department of Veterinary Microbiology, 70399University of Saskatchewan, Saskatoon, SK, Canada.

Deborah M Money (DM)

Department of Obstetrics and Gynecology, 198113University of British Columbia, Vancouver, BC, Canada.
574481Women's Health Research Institute, Vancouver, BC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH